| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
O-Acetylgalanthamine is a derivative of galanthamine, which targets acetylcholinesterase (AChE), the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft. By inhibiting AChE, galanthamine increases acetylcholine levels and enhances cholinergic neurotransmission. O-Acetylgalanthamine is expected to have similar activity, though the acetyl group may alter its potency and pharmacokinetic properties. As a natural product, it may also interact with other targets such as nicotinic receptors.
|
|---|---|
| ln Vitro |
In vitro, O-Acetylgalanthamine is a natural alkaloid with potential acetylcholinesterase inhibitory activity, similar to galanthamine. However, specific IC50 values and detailed in vitro activity data for O-Acetylgalanthamine are not extensively reported in the available literature. The compound is primarily used as a reference standard and research chemical for studying galanthamine derivatives and their biological activities.
|
| ln Vivo |
In vivo, O-Acetylgalanthamine is expected to show acetylcholinesterase inhibitory activity and potential cognitive-enhancing effects, similar to galanthamine. However, specific in vivo efficacy data for O-Acetylgalanthamine are not extensively reported. The compound is primarily used as a pharmaceutical reference standard and research chemical, and it is not approved for clinical use.
|
| Enzyme Assay |
There are no specific in vitro enzyme/receptor binding assays for O-Acetylgalanthamine as a drug target. As an acetylcholinesterase inhibitor, it may be studied in AChE activity assays using Ellman's method. The compound is incubated with AChE enzyme and the substrate acetylthiocholine, and the production of thiocholine is measured spectrophotometrically at 412 nm. The IC50 is determined from dose-response curves. However, detailed protocols for this specific compound are not extensively reported.
|
| Cell Assay |
There are no specific in vitro cellular assays for O-Acetylgalanthamine as a pharmacologically active compound. As an AChE inhibitor, it can be tested in neuronal cell cultures or neuroblastoma cell lines expressing AChE. Cells are treated with various concentrations of the compound (typically 1-100 μM) for 1-24 hours, and AChE activity is measured in cell lysates. Cell viability is assessed using MTT assays. However, detailed protocols for this specific compound are not extensively reported.
|
| Animal Protocol |
There are no specific in vivo animal studies for O-Acetylgalanthamine as a pharmacologically active compound. As a galanthamine derivative, it may be studied in rodent models of cognitive impairment (e.g., scopolamine-induced amnesia). The compound would be administered orally or intraperitoneally, and cognitive function would be assessed using Morris water maze or novel object recognition tests. However, specific protocols for this compound are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of O-Acetylgalanthamine are not extensively reported. The compound has a molecular weight of 329.39 and is expected to have moderate lipophilicity. As an acetylated derivative of galanthamine, it may have different pharmacokinetic properties compared to the parent compound, including altered absorption, distribution, metabolism, and excretion. Specific PK parameters are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of O-Acetylgalanthamine is not extensively reported. As a galanthamine derivative, it may have similar toxicity to galanthamine, including gastrointestinal and neurological effects at high doses. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute toxicity in rodents and cytotoxicity assays in neuronal cell lines. No specific genotoxicity data are reported.
|
| Additional Infomation |
Reports indicate that daffodils (Narcissus pseudonarcissus) contain O-acetylgalantamine, and relevant data is available for reference.
O-Acetylgalanthamine (CAS 25650-83-3, O-AGLA) is an acetylated alkaloid derived from Narcissus pseudonarcissus, and a derivative of the acetylcholinesterase inhibitor galanthamine. It has a molecular formula of C19H23NO4 and a molecular weight of 329.39. The compound is used as a pharmaceutical reference standard and research chemical. It is not approved for clinical use and is available for research purposes only. |
| Molecular Formula |
C19H23NO4
|
|---|---|
| Molecular Weight |
329.39
|
| Exact Mass |
329.163
|
| CAS # |
25650-83-3
|
| PubChem CID |
10131512
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.359
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O=C(O[C@H]1/C=C\[C@@]24c3c(O[C@H]2C1)c(OC)ccc3CN(C)CC4)C
|
| InChi Key |
ZTWNMOVEDXUICV-QOKNQOGYSA-N
|
| InChi Code |
InChI=1S/C19H23NO4/c1-12(21)23-14-6-7-19-8-9-20(2)11-13-4-5-15(22-3)18(17(13)19)24-16(19)10-14/h4-7,14,16H,8-11H2,1-3H3/t14-,16-,19-/m0/s1
|
| Chemical Name |
[(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0359 mL | 15.1796 mL | 30.3591 mL | |
| 5 mM | 0.6072 mL | 3.0359 mL | 6.0718 mL | |
| 10 mM | 0.3036 mL | 1.5180 mL | 3.0359 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
